Menu Search
Equities

SCHOTT Pharma AG & Co KgaA

1SXPX:GER

SCHOTT Pharma AG & Co KgaA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)29.18
  • Today's Change0.48 / 1.67%
  • Shares traded14.98k
  • 1 Year change+0.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year SCHOTT Pharma AG & Co KgaA grew revenues 9.43% from 821.14m to 898.60m while net income improved 21.11% from 125.38m to 151.84m.
Gross margin34.18%
Net profit margin15.90%
Operating margin19.21%
Return on assets11.82%
Return on equity21.23%
Return on investment16.42%
More ▼

Cash flow in EURView more

In 2023, cash reserves at SCHOTT Pharma AG & Co KgaA fell by 4.44m. However, the company earned 181.65m from its operations for a Cash Flow Margin of 20.21%. In addition the company used 171.41m on investing activities and also paid 11.40m in financing cash flows.
Cash flow per share1.41
Price/Cash flow per share20.76
Book value per share5.10
Tangible book value per share4.89
More ▼

Balance sheet in EURView more

SCHOTT Pharma AG & Co KgaA has a Debt to Total Capital ratio of 10.86%, unchanged from the previous year.
Current ratio1.41
Quick ratio1.06
Total debt/total equity0.1221
Total debt/total capital0.1086
More ▼

Growth rates in EUR

Year on year, growth in earnings per share excluding extraordinary items increased 21.11%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		5.45
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.